Management of Hospitalized Patients with Pneumonia

Diagnostic Testing and Initial Management

• A chest radiograph is mandatory for all hospitalized patients, and laboratory tests, including complete blood count, serum electrolytes, urea, and liver function tests, C-reactive protein, and oxygenation assessment, should be performed 1
• Blood cultures should be collected before antibiotic administration, and sputum cultures should be collected from patients who can produce purulent samples and haven't received prior antibiotics 1
• The Infectious Diseases Society of America recommends prompt empiric antibiotic therapy based on pneumonia severity, risk factors for multidrug-resistant pathogens, and local antibiogram data, along with appropriate diagnostic testing, supportive care, and monitoring for clinical response 2
• The European Society of Clinical Microbiology and Infectious Diseases recommends selecting antibiotic therapy for pneumonia based on severity of illness, treatment setting, and risk factors for specific pathogens, with empiric treatment initiated as soon as possible after diagnosis to reduce mortality and morbidity 3

Antibiotic Therapy

• The Infectious Diseases Society of America recommends one of the following antibiotics: Piperacillin-tazobactam, Cefepime, Levofloxacin, Imipenem, or Meropenem, and for patients with severe pneumonia or specific risk factors, one of the above antibiotics plus Vancomycin or Linezolid should be used 2
• For patients without risk factors for Pseudomonas aeruginosa, recommended regimens include non-antipseudomonal cephalosporin III (ceftriaxone) + macrolide, or moxifloxacin or levofloxacin (750mg daily) monotherapy, or aminopenicillin/β-lactamase inhibitor ± macrolide, as recommended by the European Society of Clinical Microbiology and Infectious Diseases 3
• For patients with risk factors for Pseudomonas aeruginosa, recommended regimens include antipseudomonal cephalosporin (ceftazidime, cefepime) or acylureidopenicillin/β-lactamase inhibitor (piperacillin-tazobactam) or carbapenem (meropenem preferred) PLUS ciprofloxacin OR macrolide + aminoglycoside (gentamicin, tobramycin, amikacin), as recommended by the European Society of Clinical Microbiology and Infectious Diseases 3
• First-line therapy options for healthy adults include amoxicillin, doxycycline, or a macrolide (azithromycin), as recommended by the Infectious Diseases Society of America 4
• First-line therapy options for adults with comorbidities include β-lactam (amoxicillin/clavulanate) plus a macrolide or a respiratory fluoroquinolone (levofloxacin, moxifloxacin), as recommended by the Infectious Diseases Society of America 4
• Recommended regimens for atypical pathogens include doxycycline, macrolide, levofloxacin, or moxifloxacin for Chlamydophila pneumoniae, levofloxacin (preferred), moxifloxacin, or azithromycin ± rifampicin for Legionella spp., and doxycycline, levofloxacin, or moxifloxacin for Coxiella burnetii, as recommended by the European Society of Clinical Microbiology and Infectious Diseases 3
• Recommended regimens for aspiration pneumonia include β-lactam/β-lactamase inhibitor, clindamycin, or cephalosporin + metronidazole for hospital ward patients, and clindamycin + cephalosporin for ICU or nursing home patients, as recommended by the European Society of Clinical Microbiology and Infectious Diseases 3

Monitoring and De-escalation of Therapy

• Serial vital signs, including temperature, respiratory rate, blood pressure, heart rate, and oxygen saturation, should be monitored 1
• De-escalation of therapy should be performed by narrowing the antibiotic spectrum based on culture results 2, 5
• Switching from IV to oral therapy should be considered when the patient is clinically stable, including being hemodynamically stable, having improving respiratory status, being able to take oral medications, and having normal gastrointestinal function 5
• The minimum duration of therapy for community-acquired pneumonia (CAP) is 5 days, with the patient being afebrile for 48-72 hours, as recommended by the Infectious Diseases Society of America 4, 6, 3
• Treatment should be for a minimum of 5 days, with the patient being afebrile for 48-72 hours and having no more than one CAP-associated sign of clinical instability before discontinuing antibiotics, as recommended by the Infectious Diseases Society of America 6
• Longer duration may be needed if initial response is delayed or complications develop, and clinical response should be assessed within 48-72 hours of starting treatment, as recommended by the Infectious Diseases Society of America 6, 3

Prevention and Antibiotic Stewardship

• Vaccination against pneumococcus and influenza, smoking cessation, and measures to prevent aspiration are fundamental in preventing both types of pneumonia, as recommended by the Infectious Diseases Society of America [@6@]
• Hand hygiene, elevating the head of the bed, and avoiding unnecessary intubation are also crucial in preventing hospital-acquired pneumonia (HAP), as recommended by the Infectious Diseases Society of America [@6@]
• The most effective antibiotic stewardship for CAP involves using the narrowest spectrum antibiotics appropriate for the clinical situation, limiting treatment duration to 5-7 days for most cases, and implementing systematic approaches to guide appropriate prescribing practices, as recommended by the Infectious Diseases Society of America 7
• The following table summarizes the activity of various antibiotics against drug-resistant Streptococcus pneumoniae (DRSP):